Methods for treating coronavirus infection, such as an infection caused by SARS-CoV-2, in a subject in need thereof include administering to the subject a therapeutically effective amount of a composition comprising an isolated polypeptide targeting the spike protein and the transmembrane region of the coronavirus envelope protein. Compositions include isolated polypeptides complementary to residues 30-38 of the envelope protein transmembrane region.

The present disclosure generally relates to, inter alia, to nucleic acid constructs encoding a modified enterovirus genome that is devoid of partial or complete nucleic acid sequences encoding viral structural proteins. The disclosure also provides compositions and methods useful for producing defective interfering particles (DIPs) of enteroviruses, and for the prevention and/or treatment of various health conditions such as immune diseases and viral infections.

A preparation method of an interfering peptide targeting SARS-CoV-2 N protein includes the following steps: designing an interfering peptide segment targeting amino acids located in a dimerization domain of the SARS-CoV-2 N protein; fusing the interfering peptide segment with HIV-TAT; modifying the interfering peptide segment fused with HIV-TAT into a reverse isomer to obtain an amino acid sequence of a final interfering peptide NIP-V; and synthesizing the interfering peptide NIP-V using D-amino acids as raw materials. The above-mentioned interfering peptide drug NIP-V is able to interact with the dimerization domain of the SARS-CoV-2 N protein, inhibit the oligomerization of N protein, and then relieve the inhibition for innate immunity by the N protein, so as to achieve the purpose of inhibiting the replication of SARS-CoV-2 virus in cells and animals.

Described herein are compositions defective SARS-CoV-2 constructs and particles that can interfere with or block infection of uninfected cells and methods for generating such defective SARS-CoV-2 constructs and particles. The compositions and methods described herein are useful for treatment of SARS-CoV-2 infections.

There is provided a decoy transcript derived from a ssRNA virus (WV), the transcript comprising at least one of a 5′UTR of the WV, a genomic packaging signal (GPS) of the WV, a 3′UTR of the WV, and an exogenous stop codon.

The present invention addresses the problem of providing a more convenient method for in vitro proliferating a virus belonging to the family Coronaviridae at high proliferation accuracy. This problem is solved by an in vitro virus proliferation method, said method comprising a step for culturing kidney-derived cells, which have been contacted with the virus belonging to the family Coronaviridae, with a use of a cell culture medium to which a protease having an optimum pH of from 7 to 9 is added.

The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus classifiable as belonging to the Order: Nidovirales; Family: Coronaviridae; Subfamily: Coronavirinae; Genus: Betacoronavirus; and non-Lineage A, non-Lineage B or non-Lineage D, human betacoronavirus. The invention also provides a human virus having a receptor binding domain (RBD) capable of binding to a dipeptidyl peptidase 4. The invention also provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.

The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus classifiable as belonging to the Order: Nidovirales; Family: Coronaviridae; Subfamily: Coronavirinae; Genus: Betacoronavirus; and non-Lineage A, non-Lineage B or non-Lineage D, human betacoronavirus. The invention also provides a human virus having a receptor binding domain (RBD) capable of binding to a dipeptidyl peptidase 4. The invention also provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.

Provided herein are compositions, combinations, and methods comprising Canine Respiratory Coronavirus (CRCoV), which are effective in treating or preventing respiratory infections associated secondary pathogens, such as Bordetella bronchiseptica, in animals.

Described herein is a composition and method of preventing COVID-19 with lipid-peptide fusion antiviral therapy.